This is a study to compare the safety and effectiveness of Vytorin and Lipitor in elderly patients with high cholesterol who are at high or moderately high risk for coronary heart disease. This national study is currently recruiting patients.
Read moreAnother week, another set of studies calling into question the benefits and risks of a widely used drug. This time it's Vytorin, a... Read more »
The makers of Vytorin®, Merck/Schering-Plough Pharmaceuticals, recently issued a controversial press release about the Enhance Study that... Read more »
This is a study to evaluate the safety and effectiveness of Vytorin versus Lipitor in elderly patients with high cholesterol who are at high to... Read more »
Patients taking Vytorin are more likely to reduce their LDL ("bad") cholesterol than those taking Lipitor, says Schering-Plough, maker of Vytorin.... Read more »
Vytorin lowers bad cholesterol more effectively than Liptor in patients who have both Type 2 diabetes and high cholesterol, a new study has found.... Read more »
Researchers say Vytorin may be a better choice than Lipitor for lowering cholesterol in people with Type 2 diabetes. In several recent clinical... Read more »
Drugmakers Merck and Schering-Plough are teaming up to make a new combination cholesterol medication that will compete with Vytorin. Vytorin is a... Read more »